Frontiers in Oncology (Jan 2022)

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors

  • Farbod Shojaei,
  • Bob Goodenow,
  • Gloria Lee,
  • Fairooz Kabbinavar,
  • Mireille Gillings

DOI
https://doi.org/10.3389/fonc.2021.768685
Journal volume & issue
Vol. 11

Abstract

Read online

HBI-8000 is a small molecule inhibitor of class I HDACs and has been approved for the treatment of PTCL, ATL and, in combination with exemestane, in a subpopulation of breast cancer. Given the roles of HDACs in normal and cancerous cells, there are currently multiple clinical trials, by HUYABIO International, to test the efficacy of HBI-8000 in monotherapy or in combination settings in leukemias and in solid tumors. The current review is focused on the applications of HDACi HBI-8000 in cancer therapy and its potential in combination with DDR agents.

Keywords